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To obtain a more integrated understanding of the different breast cancer phenotypes and to investigate whether bio-
molecular proﬁles can distinguish between speciﬁc histotypes, we explored the interrelations among several biologic variables
indicative of, or related to, hormone dependence, proliferation and apoptosis control, and angiogenesis in ductal and lobular
carcinomas, the most common histotypes. Oestrogen and progesterone receptors, tumour proliferative activity, the expression
of cyclin A, p16
ink4A, p27
kip1, p21
waf1, p53, bcl-2, and levels of vascular endothelial growth factor and hypoxia-inducible factor-
1a (HIF-1a) were evaluated in 190 in ductal and 67 lobular carcinomas. Our ﬁndings support the hypothesis that in ductal and
lobular carcinomas are two distinct, partially phenotypically unrelated entities, the latter being characterised by the presence of
features indicative of differentiation such as oestrogen receptors, low proliferation and lack of p53 expression and associated
with low vascular endothelial growth factor content compared to angiogenesis in ductal carcinomas. Conversely, no signiﬁcant
difference was found between lobular carcinomas and in ductal carcinomas considering the frequency distribution of PgR-
positive cases, cyclin-dependent kinase inhibitors acting at the G1/S boundary, bcl-2 and HIF-1a protein expression. Although
both generally deﬁned as hormone responsive, in ductal and lobular carcinomas are also characterised by biologic patterns in
which proteins related to hormone responsiveness, cell-cycle control, apoptosis and angiogenesis were differently associated.
This ﬁnding suggests the need to reﬁne breast cancer characterisation in order to provide detailed information about
individual tumours, or subsets of tumours, that will help in deﬁning optimal treatment approaches.
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Despite its unique origin at the terminal duct–lobular unit
(Lakhani et al, 1999) carcinoma of the breast is a very heteroge-
neous disease, due to the progressive gain or loss of functions
accumulated during the expansion of the original transformed
clone. In particular, inﬁltrating ductal (IDC) and lobular carcino-
mas (ILC) (the most frequently observed varieties of invasive
breast cancer, accounting for 70–75% and 10–14% of all invasive
tumours, respectively) are characterised by differences in their
histological structures and natural history (Harris et al, 1992). In
fact, even though following conservative surgery and radiation
therapy patients with an ILC have an outcome similar to patients
with IDC (Peiro et al, 2000), they show a different metastatic
pattern, since bone marrow and peritoneum metastases are more
prevalent in patients with ILC than in those with IDC (Borst
and Ingold, 1993; Jain et al, 1993). ILC and IDC appear to be quite
different, even in their biologic features. For instance, they differ in
hormone receptor proﬁle and proliferative activity – ILC are more
frequently oestrogen (ER) and progesterone receptor (PgR) positive
and slowly proliferating than IDC (Kruger et al, 1999). A different
relation to angiogenesis has been recently shown and a lower
expression of vascular endothelial growth factor (VEGF), the most
selective and potent angiogenic factor till now identiﬁed (Ferrara,
1999) in ILC than in IDC has been described (Lee et al, 1998).
Translational studies have produced a large amount of biologic
information on breast cancer. However, for the complex inter-rela-
tions among the cellular mechanisms involved in breast tumour
growth and progression, this information has not always been eval-
uated as part of integrated pathways. In addition, most of these
investigations focused almost exclusively on the ductal subtype or
did not separately analyse the different histotypes. On the contrary,
the analysis of bio-molecular proﬁles of the two histotypes, taking
into consideration those biomarkers which are, singly, clinically
relevant, could elucidate the distinctiveness of breast carcinoma
subtypes and might provide information to understand speciﬁc
metastatic patterns.
In an effort to obtain a more integrated understanding of the
different breast cancer phenotypes, and to investigate whether
bio-molecular proﬁles can distinguish between the two most
common histotypes, we explored the inter-relations among several
biologic variables (consolidated or of a more recent acquisition)
related to hormone dependence (ER and PgR), proliferative activity


































Revised 2 July 2002; accepted 11 July 2002
*Correspondence: Danila Coradini; Unita ` Operativa Determinanti Biomo-
lecolari nella Prognosi e Terapia, Dipartimento di Oncologia Sperimentale,
Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy;
E-mail: coradini@istitutotumori.mi.it
British Journal of Cancer (2002) 87, 1105–1111
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comangiogenesis (VEGF and hypoxia-inducible factor-1a (HIF-1a)) in
IDC and ILC.
MATERIALS AND METHODS
We studied 257 primary invasive breast carcinomas: 190 IDC and
67 ILC (pure or as main histotype in association to ductal histo-
type) obtained from patients submitted to surgery from May
1991 to May 1994 at the Istituto Nazionale Tumori of Milan.
IDC and ILC were matched for patient age (median age: 57 years
for both IDC and ILC), tumour size (median diameter: 1.9 and 2.0
for IDC and ILC, respectively) and axillary lymph nodes involve-
ment (presence of node-positive cases, 21 and 18%, respectively).
Fresh tumour material was obtained immediately after surgery.
The tumour specimen was in part incubated with
3H-thymidine,
ﬁxed in neutral 10% buffered formaldehyde and then processed
for conventional histological procedures for proliferative activity
determination according to Silvestrini et al (1994) and for the in




kip1 and cyclin A, in part frozen in liquid nitrogen and stored
at 7808C for ER and PgR detection by ligand-binding assay, as
previously described (Ronchi et al, 1986), and for the determina-
tion of VEGF and HIF-1a levels (Table 1). The determination of
proliferation index and ER or PgR was performed within National
Quality Control Programs (Piffanelli et al, 1989; Silvestrini, 1991)
recently activated in Italy, also for p53 and bcl-2 expression (Para-
diso et al, manuscript in preparation).
In situ determinations
Proliferative activity was evaluated as the fraction of
3H-thymidine
incorporating cells and was expressed as
3H-thymidine labelling
index (TLI) as previously described (Silvestrini et al, 1994). The
expression of p53 and bcl-2 was evaluated by immunohistochemis-
try on 4-mm–thick, parafﬁn-embedded sections as described
elsewhere (Silvestrini et al, 1994). Expression of the other cell
cycle-related proteins was immunohistochemically detected using
monoclonal antibodies against p16
ink4A (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), p21
waf1 (Calbiochem, La Jolla, CA, USA),
p27
kip1 (BD Transduction Laboratories, San Diego, CA, USA),
and cyclin A (Novocastra Laboratories Ltd, Newcastle upon Tyne,
UK) with dilutions, incubation times and procedures described in
Table 1. Sections were processed for the avidin–biotin–peroxidase
method (Vectastain ABC kit; Vector Laboratories, Burlingame, CA,
USA). Negative controls were obtained by omission of primary
antibodies, and tumours previously characterised by a high expres-
sion of each antigen were used as positive controls. The fraction of
tumour cells positive at a cytoplasmic (for bcl-2), cytoplasmic and
nuclear (for p16
ink4A), or at a nuclear level (for the other antigens)
was evaluated independently by two observers by scoring a total of
1000–3000 tumour cells and was deﬁned as the percentage ratio
between positive and total number of tumour cells.
HIF-1a and VEGF determinations
HIF-1a and VEGF expression was evaluated on tumour nuclear
and cytosolic fractions stored in our frozen bank following ER
and PgR determination. VEGF was measured by a quantitative
enzyme immunoassay technique (Quantikine human VEGF, R&D
Systems, Minneapolis, MN, USA) according to manufacturer’s
instructions and expressed as pg of VEGF protein per mg of cyto-
solic protein (Coradini et al, 2001). HIF-1a levels were determined
by Western blot analysis using the commercially available mono-
clonal antibody (H1a67, Abcam, Cambridge, UK). b-Actin was
used as an internal control and was detected with a speciﬁc mono-
clonal antibody (Sigma Chemical, St. Louis, MO, USA). MCF7, a
human breast cancer cell line that overexpresses HIF-1a, was used
as a positive control. Immune complexes were detected using the
ECL chemoluminescent system, and bands were detected by a
ScanJet IIIcx/T, quantiﬁed by TotalLab software (Nonlinear
Dynamics, Durham, NC, USA), normalised according to the inter-
nal standard, and expressed as normalised densitometric units
(NDU). Before using actin bands to normalise the results, the
presence of a linear range of protein concentration (i.e., a propor-
tional increase in the actin signal by increasing the amount of
starting protein concentration) was veriﬁed.
Statistical analysis
The cut-off values (Table 1) used to discriminate between slowly or
rapidly proliferating tumours, with or without steroid receptors
and expressing p53 or bcl-2, proved to be biologically and clinically
relevant in previous studies on large series of primary breast
cancers in different clinical situations (Silvestrini et al, 1994;




cyclin A, we used cut-off values that in preliminary analyses
provided relevant prognostic information (Daidone et al, 2000b).
For VEGF and HIF-1a median values were used as cut-off.
The chi-square test was used to assess the statistical signiﬁcance
of differences in the frequency distribution of tumour features
considered as categorical variables, whereas the Kruskal–Wallis test






























Table 1 Reagents, dilutions, incubation times, detection methods and threshold levels adopted
Marker Assay Reagent Source Concentration/ dilution Incubation time Antigen retrieval Cut-off
TLI ARG
3H-thymidine Amersham 6 mCi/ml, 1 h at 378C 3% of labelled cells
s.a. 25 Ci/mmol
cyclin A IHC mouse MoAb (6E6) Novocastra NCL 1:300 ON at 48C MW, citrate buffer 5% of +ve cells
p16
ink4 IHC mouse MoAb (F12) Santa Cruz 1:100 1 h at RT 50% of +ve cells
p27
kip1 IHC mouse MoAb (57) Transduction Lab 1:300 1 h at RT MW, citrate buffer 10% of +ve cells
p21
waf1 IHC mouse MoAb (EA10) Calbiochem 1:50 1 h at RT 1% of +ve cells
p53 IHC mouse MoAb (Pab 1801) Calbiochem 1:50 1 h at RT 5% of +ve cells
bcl-2 IHC mouse MoAb (124) Dako 1:40 1 h at RT MW, citrate buffer 30% of +ve cells
ER LBA
125I-estradiol NEN 2.5 nM ON at 48C 10 fmol mg
71 protein
PgR LBA
3H-Org2058 Amersham 2.5 nM ON at 48C 25 fmol mg
71 protein
VEGF Elisa mouse MoAb R&D Systems ON at 48C 63* pg mg
71 protein
HIF-1a WB mouse MoAb(H1a67) Abcam 1:1000 1.5 h at RT 6* NDU
TLI,
3H-thymidine labelling index; ER, oestrogen receptor; PgR, progesterone receptor; VEGF, vascular endothelial growth factor; HIF-1a, hypoxia-inducible factor-1a; LBA, ligand
binding assay; ARG, autoradiography; IHC, immunohistochemistry; Elisa, enzyme immune assay; WB, Western blotting; MoAb, monoclonal antibody; s.a., speciﬁc activity; ON,
overnight; RT, room temperature; MW, microwave; NDU, normalised densitometric unit. *Median value.
Biomarkers difference in lobular and ductal carcinomas
D Coradini et al
1106
British Journal of Cancer (2002) 87(10), 1105–1111 ã 2002 Cancer Research UKassess the association between pathobiologic variables. Since due to
the large number of analysis performed a proportion of the signif-
icant results should be due to chance alone, Bonferroni correction
was applied to take account of multiple comparisons. All P values
were two sided.
RESULTS
The overall series of 257 invasive breast cancers can be considered
representative of the bio-proﬁle of human breast cancers, for the
presence of ER and PgR in 84 and 69% of the cases, respectively,
the prevalence of cases not expressing p53 (about 81%), and the
presence of a similar fraction of bcl-2-positive and negative cases,
in agreement with published results on larger series of cases.
Compared to IDC (Table 2), ILC were more frequently ER+ (96
vs 80%, P=0.003), slowly proliferating (72 vs 57%, P=0.03), p53-
negative (94 vs 76%, P=0.001), cyclin A-negative (62 vs 44%,
P=0.03) and VEGF-negative (72 vs 42%, P=0.001), with a statisti-
cally signiﬁcant lower VEGF concentration (51 vs 91 pg mg
-1
cytosolic protein, P=0.0001) or median value of cyclin A-positive
cells (1.7 vs 6.2, P=0.008). Conversely, no difference was found




waf1, bcl-2 and HIF-1a protein expres-
sion.
Regardless of histotype, Spearman correlation coefﬁcient analy-
sis, adjusted by Bonferroni correction for multiple comparisons
(Table 3), indicated a statistically signiﬁcant direct relation between
ER and PgR (P=0.001), between ER or PgR and bcl-2 expression
(P=0.001 in both cases), and between PgR and p27
kip1 expression
(P=0.03). Conversely, a statistically signiﬁcant inverse relation was
observed between ER, PgR or bcl-2 and p53 expression (P=0.004,
P=0.02 and P=0.02, respectively). p21
waf1 was directly related to
TLI (P=0.002) and cyclin A expression (P=0.02). Within angiogenic
variables, only VEGF showed a direct association with tumour size
(P=0.001) and number of metastatic lymph nodes (P=0.009).
p16
ink4A and HIF-1a proved to be unrelated to all the investigated
variables, whereas a direct association was found between number
of metastatic lymph nodes and tumour size or ER (P=0.008 and
P=0.01, respectively) and between tumour size and TLI (P=0.05).
However, it should be noted that, except for the association
between ER and PgR, the correlation coefﬁcients were generally
low, thus indicating a weak association between variables.
When we analysed the relationships between biologic variables
according to histotype (Tables 4 and 5), a completely different
proﬁle of associations was observed. In fact, after eliminating weak
correlations no relationship was shared by the two histotypes. A
direct association between VEGF and tumour size (P=0.001) as
well as between PgR and bcl-2 (P=0.001) were present only in
IDC. In addition, tumour size was associated directly with TLI
(P=0.02) only in IDC. Conversely, a direct correlation between
p21
waf1 and cyclin A (P=0.03), between p16
ink4A and tumour size
(P=0.03), between VEGF and HIF-1a (P=0.05) and between
p27
kip1 and ER (P=0.05) was present only in ILC.
To investigate the presence of different proﬁles of association
between biomarkers as a function of p53 expression, the relation-
ships among biomarkers were investigated in IDC also within the
subset of p53-negative tumours, which are comparable for p53
expression to ILC, which were p53-negative in the majority (63
out of 67 or 94%) of the cases. The direct relation between ER
or PgR and bcl-2 (rs=0.38, P=0.001 and rs=0.40, P=0.001, respec-
tively), VEGF and tumour size or number of metastatic lymph
nodes (rs=0.33, P=0.001 and rs=0.27, P=0.01, respectively), TLI
and p21
waf1 (rs= 0.28, P=0.03) seemed to be independent of p53
expression, since they were observed in the subset of p53-negative
IDC, as well as in the overall IDC series. Only a direct correlation
between bcl-2 and cyclin A (rs=0.29, P=0.03) was present in p53-
negative subset and not in the overall IDC series.
When we considered hormone responsiveness (deﬁned as the
presence of at least one of the hormone steroid receptors), cell-
cycle control (as p53 expression) and angiogenesis activation (as
VEGF protein level) (Figure 1), we observed that the majority of
ILC (69%) expressed a p53-negative and VEGF-negative pheno-
type, regardless of hormone receptor status, in comparison with
33% of IDC, while only a 25% of ILC were characterised by the
p53-negative and VEGF-positive phenotype compared to 43% of
IDC.
DISCUSSION
The search for a better deﬁnition of breast carcinoma, in terms of
phenotypic portrait, led us to explore the complex interrelation-
ships existing among a panel of biologic variables representative
of cellular mechanisms involved in proliferation, apoptosis and
angiogenesis and related to tumour progression in IDC and ILC,
the two main types of invasive breast cancer. The present results
indicate that IDC and ILC, although both deﬁned as hormone-
responsive tumours (ER+ and/or PgR+ in 84 and 97% of cases,
respectively), are characterised by a different biological proﬁle in
which proteins related to hormone responsiveness, cell-cycle
control, apoptosis and angiogenesis are differently integrated. Such
ﬁndings are in keeping with preliminary results obtained by the
analysis of gene expression proﬁles of six ILCs and six IDCs (Zhao
et al, 2002). As a whole, considering the association among three of
the four biological markers exhibiting the most different pattern of
expression between the two histotypes, namely steroid receptors,
p53 and VEGF, ILC are characterised by the absence of p53 expres-
sion (thus including wild-type p53 cells but also p53 null cells)
associated with very low VEGF levels in the majority of cases,
regardless of hormone receptor status. Conversely, in IDC VEGF
is expressed at high levels in about 60% of the cases and steroid
receptors are preferentially related to the bcl-2 pathway, in agree-
ment with previous results from Ioachim et al (2000), rather
than to cyclins and cyclin-dependent kinase inhibitors pathway.
Conversely, only an inverse relation between PgR and p53 was
observed, thereby suggesting that the effect of PgR on cell differen-
tiation might be prevalently exerted through the down-regulation
of p53 expression and the up-regulation of bcl-2 expression.
Although the bcl-2 protein prevents apoptosis and in pre-invasive
lesions possibly promotes tumour development, in invasive carci-
nomas alterations in the extremely complex mechanism
regulating apoptosis may occur and apoptosis-regulating proteins
can be differently expressed and modulated in the different cellular
context. Speciﬁcally, our results of a correlation between bcl-2
overexpression and biological features of a differentiated phenotype
(high ER and PgR content and absence of p53 expression) in IDC
suggest that bcl-2 is under hormonal control and could explain the
reason why apoptosis-regulating proteins may be irrelevant to cell
death (Blagosklonny, 2001) and associated to a more favourable
clinical outcome (Silvestrini et al, 1994).
In ILC, despite the higher ER+ percentage and ER median
content than IDC, ER was related only to p27
kip1 expression.
Differently from IDC, in which tumour size and number of meta-
static lymph nodes were associated with VEGF expression, tumour
growth and nodal involvement in ILC seemed to be independent of
VEGF but related to the expression of other factors. In fact, a
direct relation between tumour size (considered as a surrogate
marker of progression) and p16
ink4A was found, thereby suggesting
a link between an aberrant accumulation of these proteins with
concurrent loss of their function and tumour proliferation (Emig
et al, 1998).
As regards the angiogenesis-related proteins, we found that, as
expected (Lee et al, 1998), IDC had a higher median VEGF concen-
tration than ILC. In addition, a strong direct relation between
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very similar to that found in a series of normal breast tissues
(43 pg mg
71 of cytosolic protein, data not shown) and an associa-
tion between VEGF and HIF-1a was observed. These ﬁndings
suggest that, in ILC, angiogenesis activation, although essential
for tumour growth and progression, does not need VEGF overex-
pression but should be promoted through angiogenic factors others
than VEGF, which might be HIF-1a-dependent. Otherwise, the
presence of anti-angiogenic factors could also be hypothesised, as
recently demonstrated in the myoepithelial cells surrounding lobu-
lar structures (Nguyen et al, 2000).
Taking into account the link found in IDC between steroid
receptors and p53 and the high VEGF expression, the observation
that, in our case series, the p53+/VEGF+ phenotype is more
frequently associated with a negative steroid receptor status






























Table 2 Distribution of biological variables according to histotype
Total cases Ductal carcinoma Lobular carcinoma
No. of cases % No. of cases % No. of cases %
Overall population 257 190 67
Tumor size (cm)
42 149 60 110 60 39 60
42 100 40 74 40 26 40
Not assessable 8 6 2
Metastatic lymph nodes
=0 205 80 150 79 55 82
405 2 2 0 4 0 2 1 1 2 1 8
Steroid receptor status (fmol/mgP)
ER 410 41 16 38 20** 3 4**
ER 410 216 84 152 80** 64 96**
PgR 425 79 31 63 33 16 24
PgR 425 178 69 127 67 51 76
Proliferative activity
TLI 43 % 156 61 108 57* 48 72*
TLI 43 % 101 39 82 43* 19 28*
p16 expression (+ve cells)
450 % 62 44 47 46 15 39
450 % 79 56 55 54 24 61
Not assessable 116 88 28
p27 expression (+ve cells)
410 % 33 18 25 18 8 16
410 % 152 82 110 82 42 84
Not assessable 72 55 17
cyclin A expression (+ve cells)
45 % 87 49 56 44* 31 62*
45 % 90 51 71 56* 19 38*
Not assessable 80 63 17
p53 expression (+ve cells)
45 % 207 81 144 76*** 63 94***
45 % 50 19 46 24*** 4 6***
p21 expression (+ve cells)
Absent 109 60 76 58 33 65
Present 74 40 56 42 18 35
Not assessable 74 58 16
bcl-2 expression (+ve cells)
430 % 107 51 79 52 28 49
430 % 102 49 73 48 29 51
Not assessable 48 38 10
VEGF (pg/mgP)
470 128 50 80 42*** 48 72***
470 129 50 110 58*** 19 28***
HIF-1a (NDU)
46 117 49 86 49 31 49
46 122 51 90 51 32 51
Not assessable 18 14 4
*P50.05; **P50.01; ***P50.005.
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surprising. Clinical studies have demonstrated a signiﬁcant relation
between p53 status and VEGF expression and their correlation with
a poor prognosis (Linderholm et al, 2000, 2001). The inter-rela-
tions among hormonal control, p53 and angiogenesis activation
could be explained by the presence in the VEGF promoter region
(Zhang et al, 2000) either of a speciﬁc cis-element recognised by
p53 or of a speciﬁc oestrogen-response element (Hyder et al,
2000). In addition, p53 protein, less frequently mutated in ILC
than in IDC (Marchetti et al, 1993), is able to down-regulate the
promoter activity of VEGF in a dose-dependent manner (Mukho-
padhyay et al, 1995) and to inactivate the HIF-1a protein
(Blagosklonny et al, 1998). Conversely, the higher incidence of
p53+ IDC compared to ILC, associated with a higher VEGF
concentration, is in keeping with a possible down-regulation of
angiogenesis by p53 tumour suppressor gene function through a
block of HIF-1 activity, with the formation of a stable complex
wild-type p53/HIF-1a (An et al, 1998) and the subsequent ubiqui-
tination of HIF-1a. Mutation of the p53 gene and the generation of
a nonfunctional protein that accumulates in the cell both inhibit
the formation of the complex and result in the constitutive avail-
ability of the transcription factor and the subsequent
transactivation of the VEGF gene (Ravi et al, 2000).
The present results provide evidence of the complex interrela-
tionships among histological subtypes, hormone responsiveness,
tumour growth, apoptosis and angiogenesis activation. They
suggest the need for a reﬁning of breast cancer characteristics in






























Table 3 Spearman rank correlation coefﬁcients between 12 pathobiological variables regardless of histotype
Size Nodes ER PgR TLI p16
ink4A p27




PgR 70.10 0.06 0.42**
TLI 0.20* 70.07 0.05 70.01
p16
ink4A 0.14 – 0.08 70.08 0.03
p27
kip1 70.04 0.14 0.17 0.22* 70.08 0.20
Cyclin A 0.15 – 70.08 70.09 0.19 70.05 70.01
p53 0.11 0.15 70.22** 70.19* 0.05 70.02 70.02 70.02
p21
waf1 0.16 – 0.20 0.16 0.27** 70.01 0.12 0.23** 70.07
bcl-2 0.02 0.03 0.41** 0.34** 0.03 70.01 0.15 0.21 70.21* 0.14
VEGF 0.28** 0.21** 70.03 70.11 0.05 0.07 70.04 0.20 0.10 0.11 70.09
HIF-1a 0.10 0.04 0.11 0.10 70.01 70.01 70.01 0.15 0.02 0.06 0.11 0.13
*P40.05; **P 40.01.
Table 4 Spearman rank correlation coefﬁcients in inﬁltrating ductal carcinoma
Size Nodes ER PgR TLI p16
ink4A p27




PgR 70.12 0.07 0.49**
TLI 0.22* 70.13 0.05 70.05
p16
ink4A 0.02 – 0.13 70.09 70.02
p27
kip1 70.09 0.12 0.12 0.18 70.06 0.18
cyclin A 0.21 – 70.10 70.08 0.16 70.03 0.04
p53 0.11 0.13 70.25** 70.23** 70.01 70.05 0.02 70.07
p21
waf1 0.12 – 0.23 0.23 0.25* 70.14 0.07 0.17 70.09
bcl-2 70.10 0.01 0.44** 0.43** 0.01 70.02 0.10 0.23 70.24* 0.10
VEGF 0.34** 0.27** 70.02 70.14 70.01 0.10 70.01 0.10 0.06 0.05 70.11
HIF-1a 0.18 0.05 0.08 0.07 0.01 0.02 70.07 0.11 70.02 70.02 0.20 0.05
*P 40.05; **P 40.01.
Table 5 Spearman rank correlation coefﬁcients in inﬁltrating lobular carcinoma
Size Nodes ER PgR TLI p16
ink4A p27




PgR 70.04 0.01 0.22
TLI 0.14 0.08 0.04 0.14
p16
ink4A 0.47* – 70.06 0.01 0.21
p27
kip1 0.08 0.26 0.39* 0.37 70.07 0.33
cyclin A 0.05 – 0.01 70.11 0.14 70.06 70.08
p21
waf1 0.28 – 0.13 70.01 0.29 0.36 0.25 0.41*
bcl-2 0.35 0.12 0.31 0.10 0.10 0.06 0.25 0.18 0.25
VEGF 0.10 70.01 0.07 0.02 0.11 0.06 0.03 0.31 0.24 70.01
HIF-1a 70.12 70.03 0.20 0.19 70.04 70.09 0.18 0.19 0.22 70.04 0.35*
*P40.05; **P40.01.
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between morphology, protein expression proﬁle and biological
behaviour. In this perspective, the advances in molecular
biotechnologies, as recently demonstrated by Perou et al (2000),
could supply information on alterations able to identify the genetic
evolutionary pathways and explain the phenotypic differences
observed in clinical tumours.
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Figure 1 Graphical representation of the relationship among hormone responsiveness (HR), deﬁned as the presence of at least one of the steroid
receptors, cell-cycle control in terms of p53 presence and angiogenesis activation, in terms of VEGF concentration in inﬁltrating ductal (IDC) and lobular
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